Meral Beksac, MD, Ankara University, Ankara, Turkey, briefly discusses adverse events (AEs) associated with the use of carfilzomib, including hypertension and cardiac insufficiency, which may be reversed with treatment interruption. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.